Skip to Content


Celebrating Courage and Hope: M. D. Anderson Observes Brain Tumor Awareness Week With Texas-Style Celebra

Celebrating Courage and Hope: M. D. Anderson Observes Brain Tumor Awareness Week With Texas-Style Celebration
Thursday, May 10, 2001, Noon - 2 p.m., In the Park Adjacent to 1100 Holcombe Blvd.
(Corner of Fannin and Holcombe)

M. D. Anderson News Release 05/09/01

Caregivers, families, physicians, nurses and many others will be celebrating the courage of patients with brain tumors and fostering hope through an event celebrating Brain Tumor Awareness Week (May 6 - 12). The festive celebration, which will spotlight patients and survivors, includes a barbeque, music and speakers who will talk about the progress being made against this deadly disease.

Last week in a ceremony in Austin, Gov. Rick Perry signed a proclamation declaring Texas Brain Tumor Awareness Week. A group from M. D. Anderson joined the governor for the signing, and the proclamation will be on display at the barbeque.

Primary brain tumors affect individuals in the prime of their lives -- those between the ages of 15 - 65 years -- and are among the most difficult to treat. Each year, more than 17,000 people in the United States are diagnosed with a primary brain tumor. They are the leading cause of cancer deaths in young people under the age of 20.

At M. D. Anderson, there has been progress against this challenging diagnosis:

  • The comprehensive Neuro-Oncology Center: M. D. Anderson has one of the most sophisticated multidisciplinary programs in the nation, bringing together experts in neuro-oncology, neurosurgery, rehabilitation, pathology, radiation oncology and radiology.
  • Intraoperative navigation: Image-guided surgery enables the surgeon to pinpoint and modify an approach to remove cancerous tissue while avoiding critical structures and minimizing exploration to uninvolved tissue.
  • New methods for neuro-imaging: New imaging techniques may someday enable surgeons to analyze the content of a mass without surgery and monitor the response to therapy.
  • Development of new drugs and combinations: M. D. Anderson is on the leading edge of developing new, less toxic drugs including Temodar, an oral medication.


© 2015 The University of Texas MD Anderson Cancer Center